PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

This article has no abstract
Epistemonikos ID: d98e3770fc60099c8e59039a1177daff069bdb44
First added on: Feb 06, 2025